Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2015

Primary Completion Date

April 27, 2018

Study Completion Date

December 20, 2018

Conditions

Critical Limb Ischemia

Interventions

DRUG

Allogenic MSC

Hypoxia-cultured human bone marrow derived mesenchymal stem cells

DRUG

Normal saline

Trial Locations (1)

Taipei Veterans General Hospital, Taipei

All Listed Sponsors

lead

Taiwan Bio Therapeutics Inc.

INDUSTRY

NCT02336646 - Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease | Biotech Hunter | Biotech Hunter